Study Finds Bisphosphonates Reduce Fracture Risk in Prostate Cancer Patients
Researchers have found that men with metastatic prostate cancer receiving androgen deprivation therapy (ADT) had a significantly lower risk of fractures when treated with a bisphosphonate alongside standard of care (SOC).
The study, published in the Annals of Oncology journal, suggests that bisphosphonates can be an effective treatment in reducing the risk of fractures in these patients.
Men with metastatic prostate cancer receiving ADT had a significantly lower risk of fractures when treated with a bisphosphonate.
In a separate note, a different study used the PanEcho model, trained on transthoracic echocardiographic (TTE) data from Yale New Haven Health System (YNHHS), to analyze echocardiographic videos.
The training data set consisted of 1.2 million echocardiographic videos across 32,265 TTE studies of 24,405 patients, with internal validation performed using a temporally distinct YNHHS cohort.
Author's summary: Bisphosphonates reduce fracture risk in prostate cancer patients on ADT.
More News
- Insider Trading: Lots of interest in Canucks’ Sherwood
- Canucks fall to dead last in NHL standings
- Charlie’s Angels 2025? Drew Barrymore, Lucy Liu’s Twinning Outfit Has Fans Manifesting
- Erika Kirk on gun violence being root problem that led to Charlie's murder, ‘I support the…’ | Hindustan Times
- AIFF Super Cup Final: What happens if East Bengal vs FC Goa ends in a draw?
- Erika Kirk rejects gun violence root cause argument
- “Charlie's Angels” Stars Drew Barrymore and Lucy Liu Reunite in Matching Outfits: ‘That’s How We Roll’
- Canucks Standings Overview
- India vs Germany in Jr. Hockey WC semis; East Bengal vs FC Goa in Super Cup final: Indian Sports LIVE, December 7
- One Of EVE Online's Biggest Alliances Has Collapsed